Categories: Events

Optimal’s synTQ under the spotlight at first digital CFC Summit

Optimal Industrial Technologies will sponsor and exhibit at the inaugural Commercializing Flow Chemistry (CFC) Summit. With flow chemistry quickly gaining momentum, the CFC digital event offers a forum for developers and producers of small molecule drug substances and products to discuss the advantages of adopting this strategy. From the 26th-27th August, attendees will be able to learn how Optimal’s Process Analytical Technology (PAT) solution, synTQ, can help companies move from batch to continuous flow chemistry.

New Delhi, August 07, 2020: PAT is crucial to the creation of successful and highly effective flow chemistry processes, delivering advanced, quality-centric process control and quality assurance. The implementation of this regulatory-compliant approach from R&D though to GMP manufacturing offers increased flexibility in the synthesis approach, safer processes, the possibility of changing starting materials together with reducing production times and costs whilst improving quality. As a result, businesses can benefit from rapid return on investment as well as optimised and streamlined processes.

On Optimal’s virtual booth at CFC summit, visitors will have access to key media and literature on the topic. In addition, they can learn more about Optimal’s PAT knowledge management platform, synTQ, which is used by over 60% of the leading pharmaceutical companies worldwide.

PAT knowledge managers are essential in PAT-driven processes, as they are the central data flow and data fusion controllers for all connected systems. synTQ also ensures that all the processes, including quality predictions and closed loop control, are executed in a regulatory-compliant way with full data integrity. It provides pharmaceutical businesses with a comprehensive and holistic view; offering responsive, data-driven control in order to optimise R&D and manufacturing activities.

Optimal is a CFC 2020 Exhibition Partner and its leading specialists will be available throughout the event to discuss how to implement PAT-driven flow chemistry and the benefits that synTQ can offer via the summit roundtables and platform networking features. More precisely, anyone who wants to find out more will be able to schedule virtual meetings or consultations with them during the summit by visiting the company’s exhibition page.

Martin Gadsby, Director at Optimal Industrial Technologies, comments: “Flow chemistry is a gamechanger for developers and producers of small molecule drug substances and products. We have already supported major pharmaceutical manufacturers in the adoption of flow chemistry from R&D to GMP production. They were able to accelerate new product development and increase manufacturing throughput in a fully regulatory compliant way. We would like to invite anyone interested in knowing more about how we can help in the implementation of PAT-driven flow chemistry solutions to get in touch with us during the summit.”

Corporate Comm India(CCI Newswire)

The Pharma Times News Bureau

Recent Posts

Bayer Introduces Bepanthen in India as New Survey Reveals Dry Skin Affects 1 in 2 Indians

·        World's no.1 skincare brand Bepanthen* launches in India, as a solution to tackle India's widespread dry skin…

5 hours ago

Lung Cancer in India: Understanding Risk Factors and the Importance of Early Detection

By Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital.…

23 hours ago

10 Winter Skin Care Tips Dermatologists Swear By

Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru  Winter weather brings a host…

4 days ago

Fighting Viral Hepatitis in India: Prevention, Risks, and the Path to Better Health

By Dr. Naveen Ganjoo, Senior Consultant - Hepatology & Integrated Liver Care, Aster RV Hospital…

4 days ago

Hon’ble Prime Minister Shri Narendra Modi Inaugurates LyfiusPharma’s Flagship Penicillin-G Facility at Kakinada, Andhra Pradesh

Under the Production Linked Incentive(PLI)scheme, Lyfius Pharma Private Limited(LyfiusPharma) invested ₹2,500 crores in Penicillin-G( Pen-G)facility…

5 days ago